Radiomics and Radiogenomics of Non-small Cell Lung Cancer - Trial NCT06331975
Access comprehensive clinical trial information for NCT06331975 through Pure Global AI's free database. This phase not specified trial is sponsored by European Institute of Oncology and is currently Completed. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 91 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
European Institute of Oncology
Timeline & Enrollment
N/A
Jun 12, 2018
Sep 14, 2023
Primary Outcome
Evaluation of the association between the status of Epidermal Growth Factor Receptor (EGFR), Anaplastic Lymphoma Kinase (ALK), Kirsten Rat Sarcoma Virus (KRAS) and nodal status,Evaluation of the association between the status of EGFR, ALK, KRAS and overall survival (OS),Evaluation of the association between the status of EGFR, ALK, KRAS and disease free survival (DFS)
Summary
In this study, the radiomic characteristics and a broad range of genetic aberrations in lung
 adenocarcinomas will be evaluated. Investigators will assess changes in the radiomic and
 genetic profiles during targeted therapies in a subset of patients harboring treatable
 mutations. Patients undergoing targeted therapies will also be evaluated for variations in
 genomic profile and radiomic signature during follow-up
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06331975
Non-Device Trial